Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 113

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 113
---
 |     | We or our licensors or strategic partners might not have been the first to file patent applications covering 
 certain of our inventions;                                                                                   |

| • |     | Others may independently develop similar or alternative technologies or duplicate any of our technologies without 
 infringing our intellectual property rights;                                                                      |

| • |     | Our pending patent applications may not lead to issued patents; |

| • |     | Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may 
 be held invalid or unenforceable, as a result of legal challenges by our competitors;                             |

| • |     | Our competitors might conduct research and development activities in countries where we do not have patent rights                   
 and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; |

| • |     | We may not develop additional proprietary technologies that are patentable; and |

| • |     | The patents of others may have an adverse effect on our business. |

Should any of these events occur, they could significantly harm our business, financial condition and results of operations. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for PTA. If we or our partners, collaborators, licensees or licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and results of operations. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all.